0.575
전일 마감가:
$0.561
열려 있는:
$0.57
하루 거래량:
228.67K
Relative Volume:
0.23
시가총액:
$51.09M
수익:
-
순이익/손실:
$-20.31M
주가수익비율:
-2.1739
EPS:
-0.2645
순현금흐름:
$-21.07M
1주 성능:
-2.54%
1개월 성능:
-8.74%
6개월 성능:
-54.37%
1년 성능:
-45.75%
Oncolytics Biotech Inc Stock (ONCY) Company Profile
ONCY을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ONCY
Oncolytics Biotech Inc
|
0.575 | 51.09M | 0 | -20.31M | -21.07M | -0.2645 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-10-06 | 개시 | Maxim Group | Buy |
2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Small-cap cancer therapy innovator raises $20M in flexible funding - MSN
Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire) - Aktiellt
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire) - Aktiellt
Buzz on the Bullboards: Energy, cannabis, and biotech shine on the TSX | 2025-04-17 | Investing News - Stockhouse
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights - Quantisnow
(ONC) Investment Performance Report (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech : reg; Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer - marketscreener.com
Oncolytic Virus Therapy Market Size, Share and Strategic - openPR.com
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz - The Malaysian Reserve
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Trend Tracker for (ONC) (ONC:CA) - news.stocktradersdaily.com
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers - Eastern Progress
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Developm - GuruFocus
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech Inc - Baystreet.ca
Small-cap cancer therapy innovator raises $20M in flexible funding | 2025-04-11 | Investing News - Stockhouse
Oncolytics secures $20 million to advance cancer therapy development - The Pharma Letter
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. - GuruFocus
Oncolytics Biotech Secures $20 Million Funding for Pelareorep Development - TipRanks
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital - Barchart.com
Oncolytics Biotech® Inc. - MENAFN.com
Private Sector Steps Up in Cancer Research as Federal Support Wavers - Baystreet.ca
Stocks In Play: Oncolytics Biotech® Inc. - Barchart.com
Stocks In Play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech’s Pelareorep Gains Attention at Key Oncology Event - TipRanks
Cancer Experts Reveal Promising Outlook for Revolutionary Immunotherapy Treatment - Stock Titan
Indo-Asian News Service - Indo-Asian News Service (IANS)
(ONC) Optimized Trading Opportunities (ONC:CA) - news.stocktradersdaily.com
What Nvidia Stock Investors Should Know About Recent Tariff Updates - The Globe and Mail
Mideast stock markets tumble as US tariffs and low oil prices squeeze energy-producing nations - The Globe and Mail
Oncolytics Biotech(R) Announces First Patient Treated in Company's AWARE-1 Window of Opportunity Study of Pelareorep in Breast Cancer - ACCESS Newswire
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies - Quantisnow
Virtu Financial LLC Invests $90,000 in Oncolytics Biotech Inc. (NASDAQ:ONCY) - Defense World
Oncolytics Biotech’s Financial Stability at Risk: Urgent Need for New Financing - MSN
What is Leede Financial’s Estimate for ONCY FY2025 Earnings? - The AM Reporter
FY2027 EPS Estimate for Oncolytics Biotech Lifted by Analyst - Defense World
TSE:ONC FY2025 EPS Estimate Lifted by Leede Financial - Defense World
HC Wainwright Has Bearish Forecast for ONCY FY2029 Earnings - Defense World
HC Wainwright Cuts Earnings Estimates for Oncolytics Biotech - Defense World
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference - GuruFocus.com
Biotech Advancing Pivotal Phase III Breast Cancer Trial - Streetwise Reports
Bridgewater Systems and Oncolytics Biotech Inc. Under Current Evaluation - ACCESS Newswire
Oncolytics Biotech (NASDAQ:ONCY) Given Buy Rating at HC Wainwright - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $3.00 by Analysts at Maxim Group - Defense World
Oncolytics Biotech: Continuing To Justify The Negativity - Seeking Alpha
Oncolytics Biotech’s Promising Advancements and Strategic Developments Drive Buy Rating - TipRanks
Oncolytics price target lowered to $3 from $5 at Maxim - TipRanks
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - PR Newswire
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):